|
Video: What is a Stock Split?
|
|
Vistagen Therapeutics is a late clinical-stage biopharmaceutical company engaging in the treatment for individuals living with anxiety, depression and other central nervous system disorders. Co.'s product candidates include: fasedienol (PH94B), which is used for treatment of social anxiety disorder; Itruvone (PH10), which is used for depression disorders; PH80, which is used for treatment of both vasomotor symptoms (hot flashes) due to menopause and migraine headaches; PH15, which is used for treatment to improve cognitive impairment caused by mental fatigue and other disorders; and AV-101, which is an oral prodrug that targets the N-methyl-D-aspartate receptor. According to our VTGN split history records, VistaGen Therapeutics has had 1 split. | |
|
VistaGen Therapeutics (VTGN) has 1 split in our VTGN split history database. The split for VTGN took place on June 07, 2023. This was a 1 for 30 reverse split, meaning for each 30 shares of VTGN owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 33.3333333333333 share position following the split.
When a company such as VistaGen Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the VTGN split history from start to finish, an original position size of 1000 shares would have turned into 33.3333333333333 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into VistaGen Therapeutics shares, starting with a $10,000 purchase of VTGN, presented on a split-history-adjusted basis factoring in the complete VTGN split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/29/2014 |
|
End date: |
04/25/2024 |
|
Start price/share: |
$14.70 |
|
End price/share: |
$4.70 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-68.03% |
|
Average Annual Total Return: |
-10.78% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$3,197.11 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
06/07/2023 | 1 for 30 |
|
|